Share

January 01, 2013; 80 (1) Article

Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis

Mark D. Cossburn, Katharine Harding, Gillian Ingram, Tariq El-Shanawany, Adrian Heaps, Trevor P. Pickersgill, Stephen Jolles, Neil P. Robertson
First published December 12, 2012, DOI: https://doi.org/10.1212/WNL.0b013e31827b5927
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
668

Share

Article Information

vol. 80 no. 1 55-61
DOI: 
https://doi.org/10.1212/WNL.0b013e31827b5927
PubMed: 
23243077
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received March 19, 2012
  • Accepted August 13, 2012
  • First Published December 12, 2012.

Article Versions

Copyright & Usage: 
© 2012 American Academy of Neurology

Author Disclosures

    1. Mark D. Cossburn, MRCP,
    2. Katharine Harding, MRCP,
    3. Gillian Ingram, PhD,
    4. Tariq El-Shanawany, MD,
    5. Adrian Heaps, PhD,
    6. Trevor P. Pickersgill, MBBch,
    7. Stephen Jolles, MD and
    8. Neil P. Robertson, MD
  1. Mark D. Cossburn, MRCP,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Katharine Harding, MRCP,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Travel grant from Biogen Idec to attend theAssociation of British Neurologists Annual Meeting inBrighton, UK, on the 28th and 29th May 2012

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Gillian Ingram, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Tariq El-Shanawany, MD,
    5. Scientific Advisory Boards:

    1. (1) Advisory board, Hayward Medical/Viriopharma(2) Advisory board, Meda/Epipen(3) MonoPepT1De-1b trial data safety monitoring board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Speaker honoraria from ALKTravel funding from ALK, CSL, BPL, Octapharma, Baxter and Grifols

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Adrian Heaps, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1) Commercial: Phadia UK/Thermo-Fisher): Travel fee and Speaker honoraria (March 2011).

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Phadia UK (Thermo-Fisher): reagent costs for an unrelated study (2010-2012).

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) Association of Clinical Biochemistry (ACB): Scholarship Award 2010 reagent costs for an unrelated study.2) Association of Clinical Biochemistry (ACB): Scholarship Award 2011 reagent costs for an unrelated study.3) National Institute for Social Care and Health Research (NISCHR) Clinical Research Assistantship 2012-2015 for unrelated studies.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Trevor P. Pickersgill, MBBch,
    7. Scientific Advisory Boards:

    1. Served on Advisory Boards for Biogen-Idec and Teva (2009)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Travel and registration fee sponsorship for ECTRIMS 2004-8 (Merck-Serono); AAN 2008/ECTRIMS 2009-10 (Biogen-Idec);ECTRIMS 2011 (Novartis)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. British Medical Association (Director) - received honoraria and travel expenses

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Previous owner of stock in Genzyme Corp. 2009-11.

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Stephen Jolles, MD and
    8. Scientific Advisory Boards:

    1. (1) CSL Behring(2)Baxter(3)Shire(4)Octapharma(5)Viropharma(6)Thermofisher(7)Biotest(8)BPL(9)Swedish Orphan Biovitrum(10)Meda

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)Clinical and Experimental Immunology, Editorial Board, 4 years

    Patents:

    1. (1)Use of IVIg in TB

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) CSL Behring(2)Baxter(3)Shire(4)Octapharma(5)Viropharma(6)Thermofisher(7)Biotest(8)BPL(9)Swedish Orphan Biovitrum(10)Meda

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)CSL Behring(2)Shire(3)Thermofisher(4)BPL(5)Association of Clinical Biochemists

    Research Support, Government Entities:

    1. (1)NISCHR - 3 year 1/10th salary

    Research Support, Academic Entities:

    1. (1)Honorary Senior Lecturer, UHW(2)Training Program Director Immunology for Wales

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Neil P. Robertson, MD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Neurology, Journal club editor May 2012 to current

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University (M.D.C., K.H., G.I., N.P.R.), and The Clinical Neurosciences Directorate (T.P.P.) and Department of Immunology, Cardiff and Vale University Local Health Board (T.E.-S., A.H., S.J.), University Hospital of Wales, Cardiff, UK.
  1. Correspondence to Dr. Robertson: robertsonnp{at}cf.ac.uk
View Full Text

Article usage

Article usage: December 2012 to May 2020

AbstractFullPdfSource
Dec 2012147023101Highwire
Jan 201311706486Highwire
Feb 20131761320Highwire
Mar 20131325854Highwire
Apr 20131404938Highwire
May 20131145039Highwire
Jun 20131142523Highwire
Jul 2013693422Highwire
Aug 2013624714Highwire
Sep 2013751713Highwire
Oct 2013732017Highwire
Nov 2013623224Highwire
Dec 2013772431Highwire
Jan 201470910Highwire
Feb 20144585Highwire
Mar 20144845Highwire
Apr 20143401Highwire
May 20142932Highwire
Jun 20142332Highwire
Jul 20143812Highwire
Aug 20142600Highwire
Sep 20142727Highwire
Oct 20143756Highwire
Nov 20142724Highwire
Dec 20141933Highwire
Jan 20152953Highwire
Feb 20151446Highwire
Mar 20152233Highwire
Apr 20151321Highwire
May 20151523Highwire
Jun 20152200Highwire
Jul 20152822Highwire
Aug 20154734Highwire
Sep 20152935Highwire
Oct 20151601Highwire
Nov 20153662Highwire
Dec 20153232Highwire
Jan 20162732Highwire
Feb 20163344Highwire
Mar 20163084Highwire
Apr 20162622Highwire
May 20162933Highwire
Jun 20162911Highwire
Jul 20162132Highwire
Aug 20163455Highwire
Sep 20163274Highwire
Oct 20164122Highwire
Nov 20162633Highwire
Dec 20163922Highwire
Jan 20172220Highwire
Feb 20172734Highwire
Mar 20171400Highwire
Apr 20171600Highwire
May 2017822Highwire
Jun 20172654Highwire
Jul 20171833Highwire
Aug 20171332Highwire
Sep 20171474Highwire
Oct 20171565Highwire
Nov 20171000Highwire
Dec 20173731Highwire
Jan 20182422Highwire
Feb 20182312Highwire
Mar 20182977Highwire
Apr 20182000Highwire
May 20182321Highwire
Jun 20181800Highwire
Jul 20182112Highwire
Aug 20181933Highwire
Sep 20181743Highwire
Oct 20181411Highwire
Nov 20182111Highwire
Dec 20181100Highwire
Jan 20193788Highwire
Feb 20192122Highwire
Mar 20193711Highwire
Apr 20195100Highwire
May 20192232Highwire
Jun 20192521Highwire
Jul 20191701Highwire
Aug 20192200Highwire
Sep 20195832Highwire
Oct 20195801Highwire
Nov 20194955Highwire
Dec 20192701Highwire
Jan 20202411Highwire
Feb 20201301Highwire
Mar 20202020Highwire
Apr 20201400Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me